A phase 2 trial of palbociclib (NCT03454919) in 15 patients with advanced acral melanoma and CDK4 pathway alterations found that 20% achieved some tumor shrinkage at 8 weeks, but only 1 was of sufficient magnitude to be considered a partial response [43]. Here, CDK4 is linked to neoplasm.